A good appointment in my view. A good match between business life cycle and skillset. James appears to have the experience required to lead ANP through trials and into commercialisation.
Many have been calling for:
1. Strong commercial experience. James has this nationally and internationally. That gives me comfort the board are resourcing for the bigger picture.
2. NASDAQ listing. James has experience here.
3. Capital market experience. James has this, and notably, experience with no-dilutive funding in biotechs.
4. Business Development. Useful for generating partnerships and broader interest from the market (which some have been explicitly calling for).
As others have already pointed out; there is nowhere for the share price of pharmaceutical companies to hide - they rest on drug performance. ANP currently has a drug that is shooting the lights out, and now someone with the right skillset to advance that technology. Let's give James a chance and see what James is capable of now that he is working with a superstar drug.
Ann: Chief Executive Officer and Managing Director Appointment, page-24
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $49.85K | 497.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 101000 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 282099 | 4 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |